Hannover Re US teams with GalenusRx to drive medication safety services

Hannover Life Reassurance Company of America and Hannover Life Reassurance Company of America (Bermuda) Ltd., collectively Hannover Re US, have entered into a cooperation agreement with GalenusRx, Inc., (GalenusRx), which sees the latter offering its technology and services to Hannover Re’s healthcare clients through their brokers and consultants.

The agreement sees Hannover Re providing its healthcare division clients with an avenue to ensuring safe and appropriate medication regimens to help avoid preventable adverse drug events (ADEs).

ADEs is renowned for being a leading cause of morbidity and mortality in the United States. It also remains a worldwide concern too.

From what we understand, GalenusRx’s medication safety technology provides patients and providers with knowledge to help prevent adverse drug events and promote better health outcomes.

The company’s proprietary platform, APPRAISE,  analyses drug-drug, multi-drug, drug-gene, and drug disease interactions to provide a risk assessment, which is individualised down to the DNA to identify risks.

At the same time, the organisation’s technology and consulting service, Lifesaving Insights, also provides an understanding of how a patient’s body responds to medication. The service also delivers personalised assessments and recommendations from Precision Clinical Pharmacists.

Julian Whitekus, VP, Health Solutions, Hannover Re US, commented: “We are delighted to partner with GalenusRx to offer its technology and services to our healthcare clients through their brokers and consultants. We believe that GalenusRx will help avoid the harmful effects of taking multiple drugs and reduce insured losses.”

Adding: “Through this partnership with GalenusRx, Hannover Re US will support its healthcare clients to improve quality and outcomes. Clients participating in accountable care and other value-based programs will also generate additional savings and will benefit from reduced total medical expenditures through GalenusRx method of avoiding predictable ADEs, thus improving their bottom line while providing better care for their policyholders.”

Peter Panageas, Chief Commercial Officer, GalenusRx, said: “GalenusRx engages eligible members in a completely different way than they have experienced in the past regarding their medication safety, enhancing the customer journey. We are proud to start an expansive partnership with Hannover Re US that enhances the member experience while supporting healthcare organizations to meet their clinical, economic, and humanistic goals.

“Through this collaboration, we are demonstrating the unique value proposition of GalenusRx and supporting the provider-pharmacist collaboration in a novel way to improve outcomes.”

This website states: The content on this site is sourced from the internet. If there is any infringement, please contact us and we will handle it promptly.